vs

Side-by-side financial comparison of Catalyst Bancorp, Inc. (CLST) and TAKEDA PHARMACEUTICAL CO LTD (TAK). Click either name above to swap in a different company.

TAKEDA PHARMACEUTICAL CO LTD is the larger business by last-quarter revenue ($4.3M vs $2.7M, roughly 1.6× Catalyst Bancorp, Inc.). Catalyst Bancorp, Inc. runs the higher net margin — 17.2% vs 3.4%, a 13.8% gap on every dollar of revenue.

Catalyst Bancorp, Inc. is a U.S.-based financial holding company that operates community banking subsidiaries. It provides a full range of retail and commercial banking products including checking and savings accounts, small business loans, residential mortgages, personal lending, and wealth management services, primarily serving local regional markets across the U.S. with a focus on individual consumers and small business clients.

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived th...

CLST vs TAK — Head-to-Head

Bigger by revenue
TAK
TAK
1.6× larger
TAK
$4.3M
$2.7M
CLST
Higher net margin
CLST
CLST
13.8% more per $
CLST
17.2%
3.4%
TAK

Income Statement — Q4 FY2025 vs Q1 FY2025

Metric
CLST
CLST
TAK
TAK
Revenue
$2.7M
$4.3M
Net Profit
$456.0K
$144.2K
Gross Margin
66.5%
Operating Margin
20.8%
5.0%
Net Margin
17.2%
3.4%
Revenue YoY
1.4%
Net Profit YoY
-27.2%
EPS (diluted)
$0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLST
CLST
TAK
TAK
Q4 25
$2.7M
Q3 25
$2.8M
Q2 25
$2.8M
$4.3M
Q1 25
$2.9M
Q4 24
$2.5M
Q3 24
$3.2M
Q2 24
$2.8M
Q1 24
$2.1M
$4.0M
Net Profit
CLST
CLST
TAK
TAK
Q4 25
$456.0K
Q3 25
$489.0K
Q2 25
$521.0K
$144.2K
Q1 25
$586.0K
Q4 24
$626.0K
Q3 24
$447.0K
Q2 24
$527.0K
Q1 24
$-4.7M
$317.0K
Gross Margin
CLST
CLST
TAK
TAK
Q4 25
Q3 25
Q2 25
66.5%
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
69.1%
Operating Margin
CLST
CLST
TAK
TAK
Q4 25
20.8%
Q3 25
21.7%
Q2 25
22.5%
5.0%
Q1 25
24.7%
Q4 24
31.2%
Q3 24
17.6%
Q2 24
23.0%
Q1 24
-284.6%
12.2%
Net Margin
CLST
CLST
TAK
TAK
Q4 25
17.2%
Q3 25
17.7%
Q2 25
18.5%
3.4%
Q1 25
20.1%
Q4 24
25.3%
Q3 24
14.2%
Q2 24
18.7%
Q1 24
-224.0%
7.9%
EPS (diluted)
CLST
CLST
TAK
TAK
Q4 25
$0.13
Q3 25
$0.13
Q2 25
$0.14
Q1 25
$0.16
Q4 24
$0.13
Q3 24
$0.11
Q2 24
$0.13
Q1 24
$-1.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLST
CLST
TAK
TAK
Cash + ST InvestmentsLiquidity on hand
$25.2M
$2.5B
Total DebtLower is stronger
$14.7M
Stockholders' EquityBook value
$81.7M
$45.1B
Total Assets
$282.9M
$92.6B
Debt / EquityLower = less leverage
0.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLST
CLST
TAK
TAK
Q4 25
$25.2M
Q3 25
$37.3M
Q2 25
$40.1M
$2.5B
Q1 25
$40.3M
Q4 24
$44.3M
Q3 24
$45.8M
Q2 24
$75.5M
Q1 24
$76.0M
$3.0B
Total Debt
CLST
CLST
TAK
TAK
Q4 25
$14.7M
Q3 25
$14.7M
Q2 25
Q1 25
Q4 24
$9.6M
Q3 24
$29.5M
Q2 24
$30.3M
Q1 24
$29.4M
Stockholders' Equity
CLST
CLST
TAK
TAK
Q4 25
$81.7M
Q3 25
$81.6M
Q2 25
$80.8M
$45.1B
Q1 25
$80.6M
Q4 24
$80.2M
Q3 24
$81.7M
Q2 24
$81.0M
Q1 24
$81.3M
$47.3B
Total Assets
CLST
CLST
TAK
TAK
Q4 25
$282.9M
Q3 25
$283.8M
Q2 25
$273.8M
$92.6B
Q1 25
$271.6M
Q4 24
$276.7M
Q3 24
$280.6M
Q2 24
$295.3M
Q1 24
$282.0M
$98.2B
Debt / Equity
CLST
CLST
TAK
TAK
Q4 25
0.18×
Q3 25
0.18×
Q2 25
Q1 25
Q4 24
0.12×
Q3 24
0.36×
Q2 24
0.37×
Q1 24
0.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLST
CLST
TAK
TAK
Operating Cash FlowLast quarter
$3.3M
Free Cash FlowOCF − Capex
$3.1M
FCF MarginFCF / Revenue
116.8%
Capex IntensityCapex / Revenue
7.1%
Cash ConversionOCF / Net Profit
7.21×
TTM Free Cash FlowTrailing 4 quarters
$5.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLST
CLST
TAK
TAK
Q4 25
$3.3M
Q3 25
$912.0K
Q2 25
$1.2M
Q1 25
$427.0K
Q4 24
$3.2M
Q3 24
$896.0K
Q2 24
$1.4M
Q1 24
$247.0K
Free Cash Flow
CLST
CLST
TAK
TAK
Q4 25
$3.1M
Q3 25
$827.0K
Q2 25
$1.1M
Q1 25
$361.0K
Q4 24
$2.7M
Q3 24
$771.0K
Q2 24
$1.2M
Q1 24
$223.0K
FCF Margin
CLST
CLST
TAK
TAK
Q4 25
116.8%
Q3 25
29.9%
Q2 25
39.7%
Q1 25
12.4%
Q4 24
110.9%
Q3 24
24.5%
Q2 24
41.5%
Q1 24
10.7%
Capex Intensity
CLST
CLST
TAK
TAK
Q4 25
7.1%
Q3 25
3.1%
Q2 25
1.2%
Q1 25
2.3%
Q4 24
17.4%
Q3 24
4.0%
Q2 24
8.0%
Q1 24
1.1%
Cash Conversion
CLST
CLST
TAK
TAK
Q4 25
7.21×
Q3 25
1.87×
Q2 25
2.21×
Q1 25
0.73×
Q4 24
5.07×
Q3 24
2.00×
Q2 24
2.64×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons